PURPOSE: Metastasis-associated in colon cancer-1 (MACC1) is a newly identified gene that plays an important role in cancer progression and metastasis. MACC1 has important functions in the differentiation, invasion, and metastasis of nonsmall cell lung cancer (NSCLC). However, the value of circulating MACC1 as a potential diagnostic and prognostic biomarker for NSCLC remains unknown. METHODS: Plasma MACC1 mRNA levels were examined in 272 patients with NSCLC, 61 with benign lung disease, and 80 healthy volunteers using reverse transcription quantitative real-time polymerase chain reaction. RESULTS: MACC1 was more highly expressed in NSCLC patients than in patients with benign disease (P < 0.001) or in healthy volunteers (P < 0.001). High MACC1 expression was significantly associated with NSCLC stage (P = 0.013) and lymph node metastasis (P = 0.016). The area under the receiver operating characteristic curve was 0.766, and the optimal cutoff value was 0.105, providing a sensitivity of 71.4 % and a specificity of 89.1 %. The diagnostic capability of circulating MACC1 mRNA was higher than that of carcinoembryonic antigen (P = 0.025) or cytokeratin-19 (P = 0.010). Furthermore, high MACC1 expression was associated with poor overall survival (OS) and disease-free survival (DFS) and predicted poor survival in NSCLC patients. Consequently, MACC1 mRNA was an independent prognostic factor of OS and DFS. CONCLUSION: We concluded that circulating MACC1 mRNA represents a potential noninvasive, diagnostic and prognostic marker for NSCLC.
PURPOSE:Metastasis-associated in colon cancer-1 (MACC1) is a newly identified gene that plays an important role in cancer progression and metastasis. MACC1 has important functions in the differentiation, invasion, and metastasis of nonsmall cell lung cancer (NSCLC). However, the value of circulating MACC1 as a potential diagnostic and prognostic biomarker for NSCLC remains unknown. METHODS: Plasma MACC1 mRNA levels were examined in 272 patients with NSCLC, 61 with benign lung disease, and 80 healthy volunteers using reverse transcription quantitative real-time polymerase chain reaction. RESULTS:MACC1 was more highly expressed in NSCLCpatients than in patients with benign disease (P < 0.001) or in healthy volunteers (P < 0.001). High MACC1 expression was significantly associated with NSCLC stage (P = 0.013) and lymph node metastasis (P = 0.016). The area under the receiver operating characteristic curve was 0.766, and the optimal cutoff value was 0.105, providing a sensitivity of 71.4 % and a specificity of 89.1 %. The diagnostic capability of circulating MACC1 mRNA was higher than that of carcinoembryonic antigen (P = 0.025) or cytokeratin-19 (P = 0.010). Furthermore, high MACC1 expression was associated with poor overall survival (OS) and disease-free survival (DFS) and predicted poor survival in NSCLCpatients. Consequently, MACC1 mRNA was an independent prognostic factor of OS and DFS. CONCLUSION: We concluded that circulating MACC1 mRNA represents a potential noninvasive, diagnostic and prognostic marker for NSCLC.
Authors: K W Lo; Y M Lo; S F Leung; Y S Tsang; L Y Chan; P J Johnson; N M Hjelm; J C Lee; D P Huang Journal: Clin Chem Date: 1999-08 Impact factor: 8.327
Authors: J L Cabrera-Alarcon; A Carrillo-Vico; J D Santotoribio; A Leon-Justel; R Sanchez-Gil; A Gonzalez-Castro; J M Guerrero Journal: Clin Lab Date: 2011 Impact factor: 1.138
Authors: M Fleischhacker; T Beinert; M Ermitsch; D Seferi; K Possinger; C Engelmann; B Jandrig Journal: Ann N Y Acad Sci Date: 2001-09 Impact factor: 5.691
Authors: Abdul K Siraj; Tariq Masoodi; Rong Bu; Shaham Beg; Saif S Al-Sobhi; Fouad Al-Dayel; Mohammed Al-Dawish; Fowzan S Alkuraya; Khawla S Al-Kuraya Journal: Am J Hum Genet Date: 2016-05-26 Impact factor: 11.025
Authors: Tao Guo; Shilei Zhao; Peng Wang; Xiaoyuan Xue; Yan Zhang; Mengying Yang; Nan Li; Zhuoshi Li; Lingzhi Xu; Lei Jiang; Lei Zhao; Patrick C Ma; Rafael Rosell; Jinxiu Li; Chundong Gu Journal: Oncotarget Date: 2017-07-18